Archive
Here you can find the archive of all Press Releases prior to 2018
Filter by date:
Showing 647 press releases before 2018
-
AstraZeneca marks a key milestone with the ‘topping out’ of new global R&D centre and HQ in Cambridge, UK
-
Tagrisso (osimertinib) receives US FDA full approval
-
AstraZeneca’s potential medicine for neuromyelitis optica spectrum disorder receives orphan designation in Europe
-
Astrazeneca to share its robust early science in oncology with the medical community at AACR 2017
-
Tagrisso approved in China as first-in-class treatment for EGFR T790M mutation-positive metastatic non-small cell lung cancer
-
AstraZeneca’s CVD-REAL study shows SGLT-2 inhibitors significantly reduced death and hospitalisations for heart failure versus other type-2 diabetes medicines
-
AstraZeneca and Circassia enter strategic collaboration in respiratory disease
-
AstraZeneca receives Complete Response Letter from US FDA for ZS-9 (sodium zirconium cyclosilicate) for hyperkalaemia
-
Lynparza Phase III SOLO-2 data demonstrate progression-free survival benefit in BRCA-mutated ovarian cancer as maintenance therapy
-
MedImmune and Sanofi Pasteur form alliance to develop and commercialise potential next-generation respiratory syncytial virus antibody MEDI8897
Latest articles and press releases
All of our latest press releases and articles are available to explore
Contact us
Gonzalo Viña
Head of Global Media Relations
+44 203 749 5916
Rob Skelding
Director Global Media Relations (Oncology)
+44 203 749 5821
Rebecca Einhorn
Director Global Media Relations (Oncology)
+1 301 398 1802
Matthew Kent
Director Global Media Relations (BioPharmaceuticals)
+44 203 749 5906
Angela Fiorin
Director Global Media Relations (BioPharmaceuticals)
+44 122 334 4690
Jennifer Hursit
Manager Global Media Relations
+44 203 749 5762
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
